Loading
Low sodium in the blood is common in cancer, especially small-cell lung cancer, and can also come from some cancer drugs, sickness or diarrhoea. Vomiting, confusion, drowsiness or a fit with low sodium is an emergency: hospital teams give a strong salt drip in small doses and check often, because raising sodium too fast can damage the brain. Then the cause is treated.
Treatment follows symptoms, not the number (Society for Endocrinology 2016): severe symptoms (vomiting, seizures, reduced consciousness, cardiorespiratory arrest) need immediate hypertonic saline whatever the cause, supervised by a senior clinician, aiming for a 5 mmol/L rise in the first hour; if limits of 10 mmol/L in 24 hours or 18 mmol/L in 48 hours are exceeded, hypertonic fluid stops and an experienced clinician considers hypotonic fluid, with or without an antidiuretic such as desmopressin, to re-lower. After the emergency, urine osmolality and urine sodium define the cause.
The Korean Society of Nephrology 2022 guideline suggests rapid intermittent boluses rather than slow continuous infusion (B, low), based on the SALSA trial (178 patients: overcorrection 17.2% against 24.2%, not significant; re-lowering treatment needed less often with boluses, 41.4% against 57.1%), and tabulates the European bolus regimen of 150 mL over 20 minutes repeated two to three times for severe symptoms; it notes the European guideline graded bolus therapy 1D. It sets a stricter limit of 8 mmol/L a day for people at high risk of osmotic demyelination. For SIAD it names fluid restriction as standard, with oral salt plus a loop diuretic, or a vaptan, second line; it suggests vaptans for moderate to severe hyponatraemia (B, low) where the European guideline recommends against them in people without moderately severe or severe symptoms. In people with brain disease, including brain tumours, it warns against fluid restriction because of volume depletion.
In cancer, SIADH is the usual cause, most often with small-cell lung cancer, from ectopic vasopressin or from anticancer and palliative drugs; vomiting and diarrhoea cause hypovolaemic hyponatraemia (The Oncologist 2012). A 2026 scoping review of 86 SCLC patients on tolvaptan reported an initial response in all cases and overcorrection in five.
Why: A very low sodium can cause no symptoms, while a moderate one can cause fits if it fell quickly.
“Severity of clinical presentation may not match the degree of hyponatraemia: profound hyponatraemia may be symptom-free, while some patients with moderate biochemistry may have significant neurological symptoms and signs.”
Why: Swelling of the brain from low sodium can kill; the cause can be found afterwards.
“Patients with severe symptoms require immediate treatment with hypertonic saline, irrespective of the cause of the hyponatraemia.”
Why: Raising sodium a little quickly relieves brain swelling; raising it too far is dangerous.
“The aim is to achieve a 5 mmol/L rise in serum Na+ within the first hour, reducing immediate danger from cerebral oedema while minimising the risk of over-rapid correction and osmotic demyelination.”
Why: In a randomised trial boluses reached the first-hour target more often and needed fewer corrections afterwards, with no more overcorrection.
“We suggest RIB administration of hypertonic saline in patients with symptomatic severe hypotonic hyponatremia (B, low).”
Korean Society of Nephrology, Korean Journal of Internal Medicine 2022 · B, low
Why: Sodium can rise faster than planned, especially once the body starts passing more urine.
“We suggest checking SNa concentration 1 hour after first hypertonic saline administration, then re-checking SNa concentration every 6 hours to adjust the administration interval or infusion rate of hypertonic saline [1].”
Korean Society of Nephrology, Korean Journal of Internal Medicine 2022
Why: Correcting too fast can cause osmotic demyelination, a permanent brain injury.
“If the limit of 10 mmol/L in the first 24 h or 18 mmol/L in the first 48 h of treatment is exceeded, hypertonic fluid should be stopped.”
Why: These people are more likely to be harmed by fast correction, and malnutrition is common in advanced cancer.
“SNa concentration should not be corrected by ≥ 10 mmol/L per day, with a more stringent limit of > 8 mmol/L per day for patients at high risk of ODS (SNa concentration ≤ 105 mmol/L, hypokalemia, alcoholism, malnutrition, and advanced liver disease) [2].”
Korean Society of Nephrology, Korean Journal of Internal Medicine 2022
Why: Treatment differs by cause: the wrong treatment, such as fluid restriction when someone is dry, can make sodium fall further.
“Measurement of urine osmolality and urine Na+ concentration are central to defining the aetiology of hyponatraemia.”
Why: These are the usual causes in cancer and need opposite treatments.
“Hyponatremia in the cancer patient is usually caused by the syndrome of inappropriate antidiuretic hormone (SIADH), which develops more frequently with SCLC than with other malignancies.”
Why: Fluid restriction lets the kidneys correct sodium slowly; tablets are added if it is not enough.
“In patients with SIAD, the standard treatment is the restriction of free water because of water retention [32].”
Korean Society of Nephrology, Korean Journal of Internal Medicine 2022
Why: Low sodium with brain disease can come from salt loss or low cortisol as well as SIADH, and becoming dry can harm the brain.
“Therefore, in the case of hyponatremia accompanying these cerebral diseases, clinicians should avoid volume depletion through water restriction [63].”
Korean Society of Nephrology, Korean Journal of Internal Medicine 2022
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
For the emergency, the guidelines read agree: severe symptoms mean immediate hypertonic saline, a first-hour rise of about 5 mmol/L, and limits of 10 mmol/L in 24 hours and 18 mmol/L in 48 hours (Society for Endocrinology 2016, drawing on the 2014 European and 2013 American guidelines). How to give it has trial evidence since 2014: the SALSA randomised trial found boluses no more likely to overcorrect than continuous infusion and less likely to need re-lowering, and the Korean 2022 guideline therefore suggests boluses (B, low). Where they disagree is chronic SIADH: the Korean guideline suggests a vaptan for moderate to severe hyponatraemia (B, low), while it reports that the European 2014 guideline recommends against vaptans in SIAD without moderately severe or severe symptoms. None of these is cancer-specific; the oncology-specific source read (The Oncologist 2012) is a review. The 2014 European guideline itself could not be read in full.
Society for Endocrinology, Endocrine Connections 2016 · Korean Society of Nephrology, Korean Journal of Internal Medicine 2022 · JAMA Internal Medicine 2021 · European Society of Endocrinology, European Journal of Endocrinology 2014 · The Oncologist 2012
Where it differs: Gives hypertonic saline as a continuous infusion (for example 0.5 to 2 mL/kg/hour, the 2013 American regimen for moderate symptoms, as tabulated by KSN 2022) rather than boluses.
Evidence: SALSA, 178 patients: no difference in overcorrection (24.2% with infusion against 17.2% with boluses, P = .26) but more re-lowering treatment with infusion (57.1% against 41.4%, P = .04).
JAMA Internal Medicine 2021 · Korean Society of Nephrology, Korean Journal of Internal Medicine 2022
Where it differs: Uses an oral vasopressin receptor antagonist when fluid restriction fails or is not possible, often during chemotherapy when fluids are needed.
Evidence: KSN 2022 suggests vaptans in SIAD with moderate to severe hyponatraemia (B, low; 12 trials, no survival benefit); a 2026 scoping review of 86 SCLC patients reported a response in all and overcorrection in five, and secondary failure that can signal tumour progression.
Korean Society of Nephrology, Korean Journal of Internal Medicine 2022 · Cancer Treatment and Research Communications 2026
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Rapid intermittent bolus of hypertonic saline for symptomatic severe hyponatraemia | B, low | Korean Society of Nephrology, Korean Journal of Internal Medicine 2022 |
| Vaptans in SIAD with moderate to severe hyponatraemia “We suggest treatment with vaptans in syndrome of inappropriate antidiuresis (SIAD) patients with moderate to severe hyponatremia (B, low).” | B, low | Korean Society of Nephrology, Korean Journal of Internal Medicine 2022 |
| Desmopressin applied individually to prevent or treat overcorrection “We suggest that desmopressin should be applied individually according to risk factors affecting overcorrection, hypertonic saline therapeutic regimen, and whether to administer dextrose solution during overcorrection in patients with hyponatremia (B, very low).” | B, very low | Korean Society of Nephrology, Korean Journal of Internal Medicine 2022 |
| Individualised treatment of hyponatraemia with brain disease “We consider it reasonable that treatment with hypertonic or isotonic saline infusion, oral sodium chloride, or fludrocortisone for the correction of hypo-osmolar hyponatremia should be individualized among patients with cerebral diseases (E).” | E (expert consensus) | Korean Society of Nephrology, Korean Journal of Internal Medicine 2022 |
| Hypertonic saline in small fixed boluses (as the European 2014 guideline grades it, reported by KSN 2022) “Although the American (2013) and European (2014) guidelines recommend administering hypertonic saline in small, fixed boluses (recommendation grade: expert opinion in the American guidelines, 1D in the European guidelines), they were not based on high-quality RCT evidence [1,2,17].” | 1D (European); expert opinion (American) | Korean Society of Nephrology, Korean Journal of Internal Medicine 2022 |
Shares Small-cell lung cancer and the tags protocol, acute-oncology, oncological-emergency.
Shares the tags protocol, acute-oncology, oncological-emergency.
Shares the tags protocol, acute-oncology, oncological-emergency.
Shares the tags protocol, acute-oncology, oncological-emergency.
Shares the tags protocol, acute-oncology, oncological-emergency.
Shares the tags protocol, acute-oncology, oncological-emergency.
Shares the tags protocol, acute-oncology, oncological-emergency.
Shares the tags protocol, acute-oncology, oncological-emergency.